Acadia Pharmaceuticals stock hits 52-week high at $29.81
Acadia Pharmaceuticals shares rose to a 52-week high around $29.76 to $29.81 and were about $29.77 at the time of reporting. The stock is up 36% over six months. Acadia reported Q2 2026 revenue of about $308 million versus a $296 million consensus, driven by Daybue sales of $125 million and steady Nuplazid. RBC, Oppenheimer, and Citizens raised price targets; analysts also cited upward earnings revisions and a Phase 2 RADIANT trial update.
How this was made
The 30-second read
Why it matters
ACAD’s 52-week high is linked to a Q2 revenue beat (about $308M vs $296M consensus), Daybue sales of $125M, steady Nuplazid performance, and increased 2026 guidance, alongside multiple analyst price target raises.
Market read
Traders get a concrete earnings datapoint (revenue beat and product sales) plus guidance and analyst target changes that can justify momentum and re-rating.
What to watch
The article does not quantify margins, cash flow, or competitive/labeling risks for Daybue and Nuplazid, which could cap upside despite revenue strength.
Background
The piece frames a late-session market move as traders pare rate-hike bets after the July CPI report, then highlights ACAD’s stock breakout and recent earnings details.
Ticker impact
Acadia hit a 52-week high near $29.8 and reported Q2 2026 revenue of about $308M, beating consensus $296M on Daybue and Nuplazid strength.
Bullish bias for continued upside follow-through, with volatility risk if guidance or trial progress disappoints.
Fresh, company-specific datapoints are provided (Q2 revenue beat, Daybue sales $125M, raised guidance, and multiple PT increases) that can drive incremental positioning beyond a generic market move.
Market effects
Reinforces positive read-through for specialty pharma sentiment around marketed products and trial progress, though impact is single-name focused.
No explicit regional macro or cross-market catalyst beyond general rate-hike bet trimming.
Limited global relevance; the driver is company-specific earnings and product sales.
Counterpoint
The move may be momentum-driven and partially priced in, so the next risk is whether raised guidance and trial milestones can sustain the pace.
Key entities
- companyAcadia Pharmaceuticals Inc.
Subject of the article, reaching a 52-week high and reporting Q2 2026 revenue beat driven by Daybue and Nuplazid.
- productDaybue
Cited as the main driver of Q2 revenue, with sales reaching $125M and exceeding expectations.
- productNuplazid
Described as steady in Q2, contributing to the revenue beat.
- clinical_programRADIANT trial
Mentioned via Phase 2 progress as a supportive factor for the outlook.
